SCHEMBL4257532

SCHEMBL4257532

Cc1nc(Nc2ncc(C(=O)O)s2)cc(N2CCN(C)CC2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIK2 Q9H0K1 14/20 0.67
SIK3 Q9Y2K2 14/20 0.67
SIK1 P57059 12/20 0.67
ABL1 P00519 12/20 0.66
KDR P35968 2/20 0.62
FLT3 P36888 2/20 0.62
KIT P10721 2/20 0.62
SRC P12931 4/20 0.57
PKMYT1 Q99640 2/20 0.56
AURKA O14965 1/20 0.56
BCR P11274 2/20 0.55
HDAC1 Q13547 1/20 0.55
EPHB6 O15197 1/20 0.54
EGFR P00533 1/20 0.54
LCK P06239 1/20 0.54
FYN P06241 1/20 0.54
CSF1R P07333 1/20 0.54
YES1 P07947 1/20 0.54
LYN P07948 1/20 0.54
RET P07949 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31688158 0.90 SIK2 (0.66) SIK2SIK3SIK1ABL1KDR
SCHEMBL14665835 0.89 ABL1 (0.64) SIK2SIK3SIK1ABL1KDR
SCHEMBL30144989 0.89 ABL1 (0.75) SIK2SIK3SIK1ABL1KDR
SCHEMBL3536666 0.89 ABL1 (0.75) SIK2SIK3SIK1ABL1KDR
SCHEMBL4252892 0.89 ABL1 (0.69) SIK2SIK3SIK1ABL1KDR
SCHEMBL26455882 0.89 SIK2 (0.64) SIK2SIK3SIK1ABL1KDR
SCHEMBL19436378 0.88 ABL1 (0.66) SIK2SIK3SIK1ABL1KDR
SCHEMBL4253276 0.88 LCK (0.66) SIK2SIK3SIK1ABL1KDR
SCHEMBL31688157 0.87 SIK2 (0.63) SIK2SIK3SIK1ABL1KDR
SCHEMBL26090180 0.87 SIK2 (0.63) SIK2SIK3SIK1ABL1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US claimed
EP-1841431-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-10-10 EP claimed
WO-2006081172-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-08-03 WO claimed
US-20250296928-A1 A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF IOMX THERAPEUTICS AG (DE) 2025-09-25 US disclosed
CN-118369321-A Synthetic schemes and procedures for preparing SIK3 inhibitors and intermediates thereof 艾奥麦克斯治疗公司 2024-07-19 CN disclosed
WO-2023067021-A1 A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF IOMX THERAPEUTICS AG (DE) 2023-04-27 WO disclosed
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US disclosed
EP-1841431-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-10-10 EP disclosed
WO-2006081172-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ABL1, BCR, PDGFRB SIK2 832/4885SIK3 1485/4885SIK1 1137/4885
US-20250296928-A1 A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF SIK3, SIK1, SIK2 SIK2 3/4885SIK3 1/4885SIK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.